Drug intelligence / Profile preview

CyMVectin

Development stage: Discontinued
Lead developer: Vical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

CyMVectin is a prophylactic DNA vaccine candidate designed to prevent congenital cytomegalovirus (CMV) infection. It utilizes a novel lipid-based adjuvant platform called Vaxfectin, which enhances the immunogenicity of DNA-based vaccines. The vaccine was developed by Vical Incorporated and is part of their pipeline focused on infectious diseases, specifically targeting the prevention of CMV transmission from mother to fetus. The mechanism involves delivering CMV antigens via plasmid DNA formulated with the Vaxfectin adjuvant to stimulate an immune response against CMV[6][9].

Brand names: CyMVectin
Other names: CyMVectin

Beyond the preview

Go deeper on CyMVectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CyMVectin.

Explore the full profile